The business model, as Panna says, comes from a “multi-tiered” approach. The company focuses on drug design, clinical trials, and diagnosis development.It’s a strategy leveraged from genomic data, innovation, and collaboration. And it benefits both side’s of the equation – the world of biotech/pharma development, as well as the patients.Now for those that are familiar with my podcast, you know that I’m picky…And you probably have heard about my show’s golden rule — To never bring on a CEO of a company I don’t personally believe in.In other words, don’t take this as a sales pitch.This company, no doubt, has long-term growth potential. And Panna has all the right answers to back it up…After looking at what’s actually on paper, it was difficult to turn away. For one, there’s high insider ownership. But more important, Cancer Genetics is working with 8 out of the top 10 biotech companies.A small company with strong partnerships with some of the biggest names in the industry is huge. This commercial traction alone is their strongest catalyst going forward.The current share price is sitting just above $2.00. And valuations are at a steep discount compared to other traditional genomic diagnosis companies.But before taking any action, note that earnings are only one week away. And considering the current shape of the industry, be sure to do some homework. Again, this is a long-term play… And resources like this interview are a great place to start.Not only is this a company that should be on everyone’s radar, this is one of those “feel good” stories. And I’m more than happy to introduce listeners to the opportunity.Links & Resources
- Stay connected to Panna Sharma and his company, Cancer Genetics
- CLICK HERE TO READ THE ENTIRE SHOW TRANSCRIPT (pdf)
Stocks Mentioned
Curzio Research publishes market commentary for informational and educational purposes. The opinions expressed and market conditions when the content is published may change. It is not personalized investment advice or an offer to buy or sell securities. Investing involves risk, including possible loss of principal. Do your own research and consult a qualified investment professional before making investment decisions.
